In contrast, the LANDSCAPE trial showed that early CTC clearance in HER2-positive breast cancer patients with brain metastases predicted intracranial response to HER2-directed therapy combined with chemotherapy and overall survival [100]. The gene discussed is ERBB2; the disease is breast cancer.